Tsai Chia-Ying, Huang Wei-Lun, Yang Shang-Chih, Huang Bo-Da, Klochkov Vladlen, Liao Shu-Lang, Wu Albert Y, Chen Wei-Li
Department of Ophthalmology, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei City, Taiwan.
School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
Invest Ophthalmol Vis Sci. 2025 Jun 2;66(6):73. doi: 10.1167/iovs.66.6.73.
To investigate the effects of topical human platelet lysate (HPL) on exposure keratopathy (EK) in a rabbit model, with a focus on its anti-inflammatory and anti-dehydration properties on the cornea.
Short-term exposure keratopathy was induced in New Zealand albino rabbits by keeping the eyelids open for four hours, followed by eyelid closure for another four hours, during which the treatment was applied. HPL, fetal bovine serum (FBS), or preservative-free artificial tears (PFAT) were administered every 15 minutes, and corticosteroid was applied every one hour during the treatment period. Corneal thickness changes and epithelial defects were assessed using anterior segment optical coherence tomography (AS-OCT) and fluorescein staining. In vivo confocal microscopy (IVCM) was used to evaluate inflammatory cell infiltration, whereas immunohistochemistry (IHC) was performed to confirm the presence of CD8+ T cells, neutrophils, and macrophages and the cell proliferation marker Ki67.
After completing the treatment, no significant difference in fluorescein staining was observed among the four groups. However, AS-OCT revealed more effective recovery of corneal thinning in the HPL- and FBS-treated groups, including improvements in epithelial, stromal, and total corneal thickness. IVCM revealed significantly reduced infiltration of inflammatory cells in the HPL-, FBS-, and corticosteroid-treated groups compared to the PFAT-treated group across the central cornea, peripheral cornea, and conjunctiva. IHC for CD8+ T cells, neutrophils, and macrophages showed similar findings. HPL-treated groups showed more Ki-67-positive cells compared to the PFAT- and corticosteroid-treated groups.
HPL treatment effectively reduced inflammation, promoted the recovery of corneal thickness, and induced cellular proliferation after dehydration, demonstrating its potential as a treatment for EK.
在兔模型中研究局部应用人血小板裂解物（HPL）对暴露性角膜病变（EK）的影响，重点关注其对角膜的抗炎和抗脱水特性。
通过使新西兰白化兔眼睑张开4小时，随后再闭合4小时来诱导短期暴露性角膜病变，在此期间进行治疗。在治疗期间，每15分钟给予HPL、胎牛血清（FBS）或无防腐剂人工泪液（PFAT），每1小时给予皮质类固醇。使用眼前节光学相干断层扫描（AS-OCT）和荧光素染色评估角膜厚度变化和上皮缺损。使用体内共聚焦显微镜（IVCM）评估炎症细胞浸润，而进行免疫组织化学（IHC）以确认CD8 + T细胞、中性粒细胞和巨噬细胞的存在以及细胞增殖标志物Ki67。
治疗完成后，四组之间荧光素染色未观察到显著差异。然而，AS-OCT显示HPL和FBS治疗组角膜变薄的恢复更有效，包括上皮、基质和角膜总厚度的改善。IVCM显示，与PFAT治疗组相比，HPL、FBS和皮质类固醇治疗组在中央角膜、周边角膜和结膜中的炎症细胞浸润显著减少。CD8 + T细胞、中性粒细胞和巨噬细胞的IHC显示出类似的结果。与PFAT和皮质类固醇治疗组相比，HPL治疗组显示出更多的Ki-67阳性细胞。
HPL治疗有效减轻炎症，促进角膜厚度恢复，并在脱水后诱导细胞增殖证明了其作为EK治疗方法的潜力。
